NeuroSense Therapeutics (NRSNW) Stock: Why It's Down Today
Updated Oct 20, 2026, 1:16 PM ET · intraday price
- Trading at $0.01 as of 1:16 PM ET, -8.18% vs the prior close of $0.01.
- Volume 4.89K shares, 0.7x its 50-day average.
- New SEC filings: 6-K (Oct 19, 2026).
- No new insider buys or sales reported since the prior session.
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Pfizer (PFE)
NRSNW slides 8.2% to $0.01. Trading at $0.01 (intraday, 1:16 PM ET), -8.18% vs the prior close of $0.01. Day range $0.01–$0.01, opened at $0.30.
NRSNW daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 20, 2026 — NRSNW slides 8.2% to $0.01
- Trading at $0.01 (intraday, 1:16 PM ET), -8.18% vs the prior close of $0.01. Day range $0.01–$0.01, opened at $0.30.
- Volume was 4.89K shares, 0.7x its 50-day average of 6.71K.
- 52-week range $0.01–$0.02; the current price sits at 1% of that range, 49.5% below the 52-week high.
Oct 19, 2026 — NRSNW jumps 4.8% to $0.01 on 1117.5x normal volume
- Closed at $0.01, +4.76% vs the prior close of $0.01. Day range $0.01–$0.02, opened at $0.30.
- Volume was 6.71K shares, 1117.5x its 50-day average of 6 — unusually heavy trading.
- 52-week range $0.01–$0.02; today's close sits at 10% of that range, 45.0% below the 52-week high.
- SEC filings that day: 6-K.
NRSNW bull case vs bear case (from the data)
- Insiders made 8 open-market purchases in the last 12 months.
- High volatility: average daily move of 8.2% over 20 sessions.
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
NRSNW latest news & SEC filings
Every SEC filing by or about NRSNW in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 19, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 13, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 2, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 25, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 9, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 27, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 13, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 6, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 31, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Jul 31, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 31, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 22, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jun 29, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jun 25, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Things to know before you trade NRSNW
- How much it moves: over the last 20 sessions the average daily move was 8.18% (largest 8.2%). That is a volatile stock.
- Liquidity: about 5.80K shares (≈$59) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.01 vs a range of $0.01–$0.02 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 0 sales; latest: Or Eisenberg bought 250,000 shares on Jun 16, 2026.
- Latest filings: 6-K Oct 19, 2026; 6-K Oct 13, 2026; 6-K Oct 2, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
NRSNW market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | 0.30 | 0.01 | 0.01 | 0.01 | 4.89K |
| Oct 19, 2026 | 0.30 | 0.02 | 0.01 | 0.01 | 6.71K |
About NeuroSense Therapeutics
NeuroSense Therapeutics (NRSNW) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in HERZLIYA, Israel. State of incorporation: Israel. Fiscal year ends December 31. SEC CIK 1875091.
NRSNW board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Cary J Claiborne | Director | Mar 18, 2026 |
| Roy Golan | Director | Mar 18, 2026 |
| Mark Leuchtenberger | Director | Mar 18, 2026 |
| Revital Mandil-Levin | Director | Mar 31, 2026 |
| Christine A Pellizzari | Director | Mar 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Alon Ben-Noon | Chief Executive Officer | Jun 17, 2026 |
| Hagit Binder | General Manager | Mar 30, 2026 |
| Or Eisenberg | Chief Financial Officer | Jun 17, 2026 |
| Niva Russek-Blum | Chief Technology Officer | Mar 30, 2026 |
| Ferenc Tracik | Chief Medical Officer | Mar 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 16, 2026 | Or Eisenberg | Buy | 250,000 | $0.80 |
| Jun 16, 2026 | Or Eisenberg | Buy | 250,000 | $0.80 |
| Jun 16, 2026 | Or Eisenberg | Buy | 250,000 | $0.80 |
| Jun 16, 2026 | Or Eisenberg | Buy | 250,000 | $0.80 |
| Jun 16, 2026 | Alon Ben-Noon | Buy | 250,000 | $0.80 |
| Jun 16, 2026 | Alon Ben-Noon | Buy | 250,000 | $0.80 |
| Jun 16, 2026 | Alon Ben-Noon | Buy | 250,000 | $0.80 |
| Jun 16, 2026 | Alon Ben-Noon | Buy | 250,000 | $0.80 |
NRSNW financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
NRSNW earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)United Therapeutics (UTHR)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Space Exploration Technologies (SPCX)Tesla (TSLA)Sandisk (SNDK)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on NRSNW
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: intraday data as of Oct 20, 2026, 1:16 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.